Design and in silico evaluation of Thiazole-Isoxazole hybrids as PPARγ-Targeted antidiabetic agents
Abstract
Introduction: Diabetes mellitus is a chronic metabolic disorder characterised by persistent hyperglycemia resulting from impaired insulin secretion, action, or both. Prolonged hyperglycemia disrupts metabolic homeostasis and increases the risk of complications, including cardiovascular disease, neuropathy, nephropathy, and retinopathy. Current therapies target multiple pathways but are limited by reduced efficacy and adverse effects. Peroxisome proliferator-activated receptor gamma (PPARγ) is a key regulator of glucose and lipid metabolism and an important therapeutic target. Thiazole and isoxazole scaffolds possess antidiabetic potential, and their hybridisation may improve efficacy and safety.
Objective: To design and evaluate a novel series of thiazole-linked isoxazole derivatives targeting the alternate ligand-binding domain of PPARγ for potential antidiabetic activity.
Result: The designed compounds (C1-C210) were docked into PPARγ (Protein Data Bank: 5 GTN), yielding nine candidates with binding affinities of -11.11 to -9.97 kcal/mol. Reference ligands included pioglitazone, Q-35, and S-35, with C139 showing the highest affinity. Molecular dynamics simulations (200 ns) confirmed stability. Advanced Trajectory analyses indicate favourable conformational sampling, correlated residue motions, and a relatively confined conformational space. In silico drug-likeness profiling further supported their activity profile.
Conclusion: In this computational study, the…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.